Corbus Pharmaceuticals announced data from the ongoing Phase 1 clinical trial for SYS6002 (CRB-701) conducted by CSPC Pharmaceutical Group, showing positive safety and efficacy results.
AI Assistant
CORBUS PHARMACEUTICALS HOLDINGS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.